Furthermore, we assessed the potential of Apolipoprotein B/A1 ratio as a marker to predict cardiovascular adverse events in a prospective cohort of Chinese CHD patients during a 5-year follow-up. This evidence concerns the gene APOB and coronary artery disorder.